Stocks
PTC Therapeutics, Inc.PTCT
NASDAQHealthcareBiotechnology$62.75
Price as of · delayed, not real-time
A biopharmaceutical company focused on developing and commercializing novel therapies for rare diseases, with a portfolio that includes treatments for Duchenne muscular dystrophy and cystic fibrosis. Its gene therapy platform and approved products make it a stock watched for pipeline catalysts and regulatory decisions.
52W Range: $61.23-$90.87
Congressional Interest in PTC Therapeutics, Inc. (PTCT)
1 member of Congress has disclosed 1 trade in PTC Therapeutics, Inc. (PTCT), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading PTCT?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2015-12-07 | MICHAEL T. MCCAUL | sell | $1K-$15K |